Proton beam therapy is an advanced form of external radiotherapy that uses high-energy proton beams instead of photon x-ray beams or electrons. Carefully measured doses of protons are delivered to the precise area needing treatment, using the latest IBA ProteusONE technology. This ensures that the delivery of proton beam therapy is highly accurate and prevents the risk of radiation reaching surrounding healthy tissue.
Radiotherapy is used to kill and destroy cancer cells. It utilises radiation in the form of high-energy x-rays, known as photons, to kill and damage the cancerous cells and prevent their growth and reproduction. It can be used as a non-surgical option to treat cancer, and it can also be used to shrink a tumour or in combination with other treatments.
The Rutherford Cancer Centres and Elekta are bringing the next generation of personalised adaptive radiotherapy technology to oncology centres across the UK, with the new MR-linac Elekta Unity now available at the Rutherford Cancer Centre North West in Liverpool.
Dr Chris Herbert qualified in medicine at Birmingham University in 2000. He trained in Clinical Oncology in Bristol and completed his oncology training as a clinical research fellow at the British Columbia Cancer Agency in Vancouver, Canada, where he specialised in stereotactic radiosurgery and the treatment of benign and malignant adult brain tumours. Appointed as consultant Clinical Oncologist in Bristol in 2011, he has an interest in technical radiotherapy, specialising in the treatment of adult brain tumours, including stereotactic radiosurgery and proton therapy.
He also has an interest in the treatment of malignant melanoma with immunotherapy and targeted treatments and has been involved in numerous international clinical trials. He has published work on stereotactic radiosurgery and external beam radiotherapy in international, peer reviewed journals.
Dr Herbert's areas of research interests include:
Proton Beam Therapy
This consultant has received training from the Rutherford Cancer Centres in the delivery of proton beam therapy. The programme, Proton Therapy Clinical Education, in conjunction with The Perelman School of Medicine at the University of Pennsylvania and IBA, the leading proton beam therapy solutions manufacturer, involves oncologists gaining practical experience in Penn’s Roberts Proton Therapy Center – one of the world’s leading centres of proton therapy research and expertise.